newsfilter
← Latest News
GlobeNewswire·

Turnstone Biologics Corp. Reports Third Quarter 2023 Financial Results and Provides Recent Business Highlights

– Promising preclinical data showcasing Turnstone's novel Selected TIL programs for solid tumors presented at SITC 2023 – – Lead program, TIDAL-01, advancing and on track in two Phase 1 trials with initial clinical